Inactivation of nfuA enhances susceptibility of Pseudomonas aeruginosa to fluoroquinolone antibiotics. Daung-nkern J, Vattanaviboon P, Mongkolsuk S J Antimicrob Chemother65p1831-2(2010 Aug)

28 Dec 2010
0
0

Inactivation of nfuA enhances susceptibility of Pseudomonas aeruginosa to fluoroquinolone antibiotics.
Daung-nkern J, Vattanaviboon P, Mongkolsuk S
J Antimicrob Chemother65p1831-2(2010 Aug)

Tags

Share this

Related Posts

Aspirin suppresses components of lymphangiogenesis and lymphatic vessel remodeling by inhibiting the NF-κB/VCAM-1 pathway in human lymphatic endothelial cells. Prangsaengtong O*, Jantaree P, Lirdprapamongkol K, Ngiwsara L, Svasti J, Koizumi K. Vasc Med. 2018 Jun;23(3):201-211.
01 Jun 2018
0

Aspirin suppresses components of lymphangiogenesis and lymphatic vessel remodeling by inhibiting the NF-κB/VCAM-1 pathway in human lymphatic endothelial cells. Prangsaengtong O*, Jantaree P, Lirdprapamongkol K, Ngiwsara L, Svasti J, Koizumi K. Vasc Med. 2018 Jun;23(3):201-211.

Aspirin suppresses components of lymphangiogenesis and lymphatic vessel remodeling by inhibiting the NF-κB/VCAM-1 pathway in human lymphatic endothelial cells. Prangsaengtong O*, Jantaree P, Lirdprapamongkol K, Ngiwsara L,Svasti J, Koizumi K. Vasc Med. 2018 Jun;23(3):201-211.
View More

Recent Posts

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)
20 Sep 2023
0

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial) Siripongboonsitti T, Ungtrakul T, Tawinprai K, Auewarakul C, Chartisathian W, Jansala T, Julsawad R, Soonklang K, Mahanonda N, Mahidol C Phytomedicine. 2023;119:155018.
View More